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Background and objectives: Atheroembolic renal disease (AERD) can require dialytic support. Because anticoagulation may
trigger atheroembolization, peritoneal dialysis may be preferred to hemodialysis. However, the effect of dialysis modality on
renal and patient outcomes in AERD is unknown.
Design, settings, participants, & measurements: A subcohort of 111 subjects who developed acute/subacute renal failure
requiring dialysis was identified from a larger longitudinal study of AERD. The main exposure of interest was dialysis
modality (peritoneal versus extracorporeal therapies). Logistic regression was used to study the probability of renal function
recovery. Times from dialysis initiation to death were studied using Cox’s regression.
Results: Eighty-six patients received hemodialysis and 25 received peritoneal dialysis. The probability of renal function
recovery was similar by dialysis modality (25% among hemodialysis patients and 24% among peritoneal dialysis patients; P
0.873). During follow-up, 58 patients died, 14 among peritoneal patients and 44 among hemodialysis patients (P  0.705). In
multivariable analysis, gastrointestinal tract involvement and use of statins maintained an independent effect on the risk of
patient death.
Conclusions: This study does not support the notion that one dialysis modality is superior to the other. However, the
observational nature of the data precludes any firm conclusions.
Clin J Am Soc Nephrol 5: 454–459, 2010. doi: 10.2215/CJN.06590909
A theroembolic renal disease (AERD) is due to the oc-clusion of small renal arteries and glomerular capil-laries by cholesterol crystals derived from atheroscle-
rotic aortic plaques (1). The severity of renal dysfunction
depends on the amount and frequency of embolic showers and
inflammatory reactions. Although chronic “spontaneous”
AERD may represent an underdiagnosed, slowly progressive
cause of ESRD mimicking nephrosclerosis, in patients develop-
ing acute or subacute renal failure AERD is usually “iatrogenic”
and dialysis may be required in 25% to 60% of the patients. In
one third of these patients renal function may recover. Recov-
ery may be related to reversal of inflammation, resolution of
acute tubular necrosis in ischemic areas, hypertrophy in sur-
viving nephrons, and reduction in intensity of embolic showers
(2–6).
Invasive aortic manipulation, including angiography and
vascular surgery, is the leading cause of AERD. However,
the disease may be rarely precipitated by anticoagulation; by
preventing the formation of a protective thrombus overlying
the ulcerated plaques; or even disrupting the fibrin cap of
atherosclerotic plaques and exposing their soft, cholesterol-
laden core to the arterial circulation (1–3,7–12). The require-
ment for systemic anticoagulation makes extracorporeal di-
alysis treatments less attractive for patients with AERD who
need dialysis. Although systemic anticoagulation can be
avoided or at least minimized initially, this can be more
difficult in the long run. On the other hand, peritoneal dial-
ysis may not be available in all facilities to treat acute kidney
injury and can be contraindicated in patients with AERD for
gut ischemia or protein losses.
Current data on benefits and harms of extracorporeal and
peritoneal dialysis therapies are scant and come from small
cohorts or case series (2,3,13–16). Although evidence from clin-
ical trials of interventions is ideally necessary to inform prac-
tice, for rare disorders cohort studies may provide relevant
information. In this study, we sought to determine whether
peritoneal dialysis is superior to extracorporeal therapies in
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terms of renal and patient outcomes of acute/subacute AERD
using data from a large longitudinal study (12).
Materials and Methods
Study Design, Patient Selection, and Follow-Up
For the purpose of the study presented here, a subcohort of 116
subjects who developed renal failure requiring dialysis treatment was
selected from a larger cohort of 354 incident cases of AERD (15).
Patients were referred to the nephrologist for kidney function impair-
ment and clinical suspicion of AERD at 12 tertiary care centers between
June 1987 and January 2006. Patients were followed from diagnosis
until death as described elsewhere (12).
Diagnostic Criteria and Prognosis Indicators
Per protocol, AERD was considered iatrogenic in the contemporary
presence of (1) renal function deterioration in atherosclerotic patients,
(2) simultaneous ischemic changes to the lower abdomen and/or ex-
tremities, (3) and one or more precipitating factors (arterial angiogra-
phy with or without angioplasty, vascular abdominal or cardiac sur-
gery, and fibrinolytic/anticoagulant therapy). A diagnosis of
spontaneous AERD was made only in the presence of (1) clinical
suspicion; and (2) a biopsy-proven deposition of cholesterol clefts in the
skin, gastrointestinal, or renal tissue or, alternatively, the disclosure of
retinal emboli upon funduscopic examination. Signs of extrarenal in-
volvement, eosinophil count, and the rate of renal function deteriora-
tion were considered to evaluate the severity of the disease (12).
Kidney Function, Clinical Presentation, and Eligibility
Serum creatinine concentration was available shortly before the pre-
cipitating event for all iatrogenic forms of AERD and in the year before
the onset of symptoms for spontaneous forms. Information on renal
function was updated at the time of AERD diagnosis, during the course
of the acute/subacute phase of renal disease, and reassessed at each
follow-up visit for those with milder forms. GFR was estimated using
the abbreviated Modification of Diet in Renal Disease formula (17).
With respect to the clinical presentation of AERD, renal failure was
defined as “acute” if a sudden 50% reduction of GFR was evident
within 1 week after the precipitating event, “subacute” if the same
deterioration occurred over 2 to 6 weeks, and “chronic” if the patient
had a stable chronic renal impairment mimicking nephrosclerosis. Pa-
tients with chronic AERD who required dialysis (two peritoneal and
three hemodialysis) were excluded.
Exposure of Interest and Outcomes
The main exposure of interest (type of dialysis) was only categorized
into two levels: peritoneal versus extracorporeal dialysis treatment. The
choice of the dialysis modality was made according to local policies,
clinical indication, and patient preferences. Peritoneal dialysis included
intermitted cycler fluid exchange by means of a dialysis machine and
continuous treatment with 4 to 5 exchanges per day. Peritoneal dialysis
was started with a cuffed permanent catheter in all patients assigned to
this modality. Extracorporeal dialysis included standard bicarbonate
schedule and mixed methods with more biocompatible membranes. In
all extracorporeal treatment schedules heparin was used as an antico-
agulant starting with a boost of 1000 IU followed by 500 to 800 IU/h.
Anticoagulation was not part of the peritoneal dialysis prescriptions.
The effect of dialysis type was studied using probabilities of renal
function recovery, defined as dialysis withdrawal, and patient survival
as outcomes.
Data Collection and Risk Factors
In addition to kidney function, demographic, clinical, and pathologic
data as well as exposure to precipitating maneuvers were recorded at
the time of AERD diagnosis. Considered vascular comorbidities were
(12): coronary artery disease (documented angina or infarction), cere-
brovascular disease (clinical signs or radiologic confirmation of a tran-
sient ischemic attack or stroke), and peripheral artery disease (symp-
toms of “claudicatio intermittens,” previous surgery for lower-limb
arterial insufficiency, and/or angiographic evidence of significant ste-
nosis in one or more peripheral vessels). The diagnosis of congestive
heart failure was based on symptoms of pump failure (New York Heart
Association classification class II or greater). Angiography or magnetic
resonance angiography were used to confirm abdominal aortic aneu-
rysm or renal artery stenosis (50% in one or both renal arteries) when
these lesions where suspected. Patients were considered diabetic if they
had been given either oral antidiabetic drugs or insulin and smokers in
case of current or previous smoking habit (at least 10 cigarettes per day
and for 10 years). Hypercholesterolemia was defined by total choles-
terol levels 220 mg/dl or if cholesterol-lowering treatment was pre-
scribed. Hypertension was defined as systolic or diastolic pressure of
140 or 90 mmHg, respectively, or if antihypertensive drugs had
been given.
Statistical Analyses
Logistic regression was used to model the probability of renal func-
tion recovery as a function of dialysis modality. Given the limited event
number and to adhere to the “rule of ten” (ten events per each esti-
mated parameter), potential confounders and their interactions were
assessed in reduced models after screening for co-linearity. These mod-
els were built on dialysis type using either (1) baseline characteristics,
traditional cardiovascular risk factors, and comorbidity; (2) precipitat-
ing factors (radiodiagnostic, interventional, or surgical procedures); (3)
markers of clinical severity of the AERD (time course of kidney func-
tion deterioration, involvement of extrarenal organ systems, eosinophil
count); (4) or treatments initiated after diagnosis to improve peripheral
oxygenation or reduce inflammation (pentoxifylline, statins, or ste-
roids). Progressive models were built on those covariates for which the
effects were significant at the level of 0.1 or modified the parameter
estimate of the exposure (dialysis modality). Times from dialysis initi-
ation to death or censoring (last follow-up visit day) were described
with the Kaplan–Meier method. Cox’s regression was used for multi-
variate analysis using stratification to control for variables for which
the effect was not of interest or violating the proportionality assump-
tion. The model building approach was the same as for logistic regres-
sion. Center effects were studied as random effects in both outcome
analyses. Model specification and overall fit were checked by re-esti-
mation and formal and graphical tests based on residuals. Calculations
were made using R (18).
Results
Baseline Characteristics, Risk Factors, and Clinical Findings
Demographic and clinical characteristics of the 111 patients
who received dialysis for acute/subacute renal failure during
the AERD study (12) are summarized in Tables 1 and 2 (40% of
the acute/subacute cases in the original cohort). Eighty-six
patients received extracorporeal treatment and 25 received
peritoneal dialysis. Of these, five patients received peritoneal
dialysis after 3 to 5 runs of hemodialysis and were still on
dialysis at the study end date.
Overall, patients tended to be male and elderly with a high
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prevalence of traditional cardiovascular risk factors and dis-
eases. Average ( SD) total cholesterol levels were 196  47
mg/dl. The estimated GFR at baseline was 38.0  16.4 ml/
min/1.73 m2. Urinalysis showed bland urine with minimal
proteinuria. The legs represented the most common extrarenal
site involved. Most patients had an iatrogenic form of AERD
(86%), with half of them experiencing two or more precipitating
factors. How the diagnosis was confirmed and the distribution
of case characteristics did not change over the study period,
except the use of statins, which increased from 40% in the initial
5 years to 65% in the last 5 years. Measured characteristics did
not vary substantially by treatment modality. As expected,
extracorporeal dialysis was more likely in hypertensive subjects
and peritoneal treatment was less likely after surgical proce-
dures.
Renal Outcome
Patients were followed for 2.9 years on average. Within 6
months of dialysis start, 28 subjects recovered sufficient kidney
function to stop dialysis therapy. Of these, four patients re-
started hemodialysis, one restarted peritoneal dialysis, and
seven died (five hemodialysis and two peritoneal dialysis) dur-
ing the study period. The probability of renal function recovery
tended to increase over time (from 11% in the first 5 years to
30% in the last 5 years) but was similar by dialysis modality
(25% among HD patients and 24% among PD patients; P 
0.873). The odds of dialysis withdrawal did not change in
multivariate analysis. None of the measured clinical character-
istics and risk factors predicted renal function recovery at the
level of significance of 0.1. Results were the same excluding
the five patients who received hemodialysis before peritoneal
dialysis.
Patient Survival
During the follow-up, 58 patients died—14 among peritoneal
patients and 44 among hemodialysis patients (Figure 1). The
yearly risk for death tended to decline over time from 0.35 in
the initial 10 years to 0.25 in the last 10 years. The relative risk
for death was similar in hemodialysis and peritoneal dialysis.
Adjustment for potential confounders did not change the result
(Figure 2). In the multivariate model only gastrointestinal tract
involvement (hazard ratio 2.6, from 1.4 to 4.9) and use of statins
(hazard ratio 0.48, from 0.28 to 0.84) maintained an indepen-
dent effect on the risk of patient death. Results did not change
excluding the five patients who received hemodialysis before
peritoneal dialysis.
Discussion
AERD arise from atherosclerotic plaques in the aorta, when
the soft, lipid-laden core of the plaques is exposed to the arterial
circulation. Catheter angiographic procedures and vascular
surgery are the most common factors identified as precipitants
of AERD. In a subgroup of patients, AERD may be caused by
anticoagulation (1–4).
As opposed to chronic AERD, in the acute and subacute
forms of AERD, dialysis support may be required in some
patients soon after an identifiable onset and a less challenging
diagnosis (2,3,5,12). In such patients, the choice of type of renal
Table 1. Baseline patient characteristics and risk factorsa
All (n  111) Peritoneal Dialysis(n  25)
Extracorporeal Dialysis
(n  86) P Value
b
Age (years) 72.0 (6.9) 71.8 (6.0) 72.1 (7.2) 0.841
Male gender 94 (84.7) 21 (84.0) 73 (84.8) 0.914
History of hypertension 93 (83.7) 17 (68.0) 76 (88.3) 0.015
Current or previous smoking habit 80 (72.0) 17 (68.0) 63 (73.2) 0.606
Diabetes 22 (19.8) 3 (12.0) 19 (22.0) 0.265
Total cholesterol 220 mg/dl 33 (29.7) 8 (32.0) 25 (29.0) 0.778
Statin use 28 (25.2) 8 (32.0) 20 (23.2) 0.376
CAD 76 (68.4) 14 (56.0) 62 (72.0) 0.127
Peripheral artery disease 66 (59.4) 15 (60.0) 51 (59.3) 0.950
Cerebrovascular disease 39 (35.2) 6 (24.0) 33 (38.3) 0.185
Heart failure 52 (46.8) 10 (40.0) 42 (48.8) 0.436
Cardiovascular diseasec 103 (92.7) 23 (92.0) 80 (93.0) 0.862
GFR 38.0 (16.4) 38.5 (15.6) 37.9 (16.8) 0.929
Chronic kidney diseased
stage 1 to 2 11 (9.9) 2 (8.00) 9 (10.4) 0.636
stage 3 60 (54.0) 12 (48.0) 48 (55.8)
stage 4 to 5 40 (36.0) 11 (44.0) 29 (33.7)
aValues expressed as mean (SD) or number (%) as appropriate.
bTwo-sided significance level.
cExcluding hypertension.
dDefined as absent/mild GFR 60 ml/min (1 ml/s, stage 1 to 2), moderate GFR 30 to 60 ml/min (0.5 to 1 ml/s, stage 3),
and severe/advanced GFR 30 ml/min (0.5 ml/s, stage 4 to 5).
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replacement therapy is influenced by facility policies and local
expertise. However, in the subset of patients with AERD and
renal failure requiring dialysis, the precipitating role of antico-
agulation raises the question of the ideal dialysis modality
(3,5,13–16). To avoid clotting within the extracorporeal circuit,
hemodialysis treatment requires systemic anticoagulation,
which may trigger new bouts of atheroemboli, reducing the
likelihood of recovery of renal function. For this reason, peri-
toneal dialysis may be preferred in these patients to avoid
heparin administration. On the other hand, AERD patients may
have contraindications to peritoneal dialysis, including mesen-
teric ischemia and protein losses in a malnourished patient.
Few studies, most retrospective, have addressed the potential
for renal functional recovery in patients with AERD and renal
failure requiring dialysis (13–16). Little is known about the
effect of the dialysis modality on the probability of renal func-
tional recovery. In one study 52 of 129 patients (40%) required
dialysis. Peritoneal dialysis and hemodialysis were used, and
11 of 52 (21%) patients recovered sufficient renal function to
allow dialysis cessation. However, the effect of dialysis modal-
ity on the probability of renal function recovery was not stud-
ied (2). In 1999, Belenfant et al. described 67 patients admitted
to a renal intensive care unit for acute AERD (3). Forty-one of
them (61%) were treated by hemodialysis, and 13 (32%) re-
gained sufficient renal function to obviate the need for dialysis.
No patient was treated with peritoneal dialysis, which was
deemed inappropriate. Hemodialysis was conducted without
systemic anticoagulation or with a very low dose of heparin
(1000 IU/session). In another study 43 patients with AERD and
renal failure severe enough to require dialysis were described;
10 received peritoneal dialysis and 33 received hemodialysis.
The rate of renal functional recovery sufficient to discontinue
dialysis was 27.9%, and the chances of renal recovery appeared
higher for the subgroup on peritoneal dialysis (14). In a more
Table 2. Clinical findingsa,b
All
(n  111)
Peritoneal Dialysis
(n  25)
Extracorporeal Dialysis
(n  86) P Valuec
AC SA All AC SA All
Precipitating factors
angiography 74 (66.6) 4 10 14 (56.0) 21 39 60 (69.7) 0.199
PCTAd 26 (23.4) 2 2 4 (16.0) 8 14 22 (25.6) 0.319
any surgerye 29 (26.1) 0 1 1 (4) 11 17 28 (32.5) 0.004
AC/FBf 36 (32.4) 3 7 10 (40.0) 7 19 26 (30.2) 0.358
No PF (spontaneous) 15 (13.5) 1 5 6 (24.0) 2 7 9 (10.4) 0.080
1 precipitating factor 46 (41.4) 3 9 12 (48.0) 11 23 34 (39.5)
2 precipitating factors 50 (45.0) 3 4 7 (28.0) 16 27 43 (50.0)
Presentation
acute (versus subacute) onset 36 (32.4) – – 7 (28.0) – – 29 (33.7) 0.591
skin manifestationsg 91 (81.9) 7 13 20 (80.0) 24 47 71 (82.5) 0.770
central nervous systemh 25 (22.5) 1 3 4 (16.0) 8 13 21 (24.4) 0.375
gastrointestinal involvementi 22 (19.8) 1 2 3 (12.0) 11 8 19 (22.0) 0.265
eosinophiliaj 75 (67.5) 7 12 19 (76.0) 16 40 56 (65.1) 0.306
Diagnosis and confirmation
clinical only 53 (47.7) 3 6 9 (36.0) 17 27 44 (51.1) 0.182
plus biopsy 55 (49.5) 4 12 16 (64.0) 12 27 39 (45.3) 0.101
plus autopsy 6 (5.4) 0 1 1 (4.0) 3 2 5 (5.8) 0.724
plus ophthalmoscopy 7 (6.3) 0 1 1 (4.0) 1 5 6 (6.9) 0.590
Treatments
statins initiated 57 (51.3) 4 10 14 (56.0) 14 29 43 (50.0) 0.597
steroids 51 (45.9) 4 6 10 (40.1) 15 26 41 (47.6) 0.498
pentoxifillyn 23 (20.7) 1 6 7 (28.0) 5 11 16 (18.0) 0.308
aVariable values expressed as n (%).
bAC, acute absolute cases; SA, subacute absolute cases.
cTwo-sided significant level (2/exact or t test as appropriate).
dPCTA, percutaneous angioplasty.
eCardiovascular surgery.
fAC/FB, anticoagulant/fibrinolytic therapy.
gPurple toes/livedo reticularis on the feet/lower abdomen.
hTransient ischemic attack, amaurosis fugax, confusional states, and gradual deterioration of neurological functions.
iAbdominal pain, diarrhea, bleeding, intestinal infarction.
jEosinophil count 500 cells/l.
Clin J Am Soc Nephrol 5: 454–459, 2010 Dialysis Modality in Atheroembolic Renal Disease 457
recent study 35 of 95 patients with AERD (37%) received dial-
ysis therapy (23 hemodialysis and 12 peritoneal dialysis), and
14 patients (40%) recovered sufficient renal function to stop
dialysis (5). Despite the limitations, mainly due to sample size
and study design, these studies suggest that renal functional
recovery can be observed in one third of the patients and may
occur after peritoneal dialysis or hemodialysis therapy.
To our knowledge, our study is the largest study evaluating
the effect of dialysis modality on renal functional recovery and
patient survival in the subgroup of patients with AERD requir-
ing dialytic support. Of 354 patients (32.7%) enrolled in a
multicenter study (12), 116 received dialysis. After exclusion of
those with chronic AERD (n  5), 111 subjects with acute/
subacute forms (40%) required dialysis. Of these, 25 patients
were treated with peritoneal dialysis and 86 with hemodialysis.
Dialysis was temporary in 28 patients (25%). However, the
probability of renal function recovery at 6 months was similar
by dialysis modality. In addition, dialysis modality did not
seem to affect the high risk for death of these patients (0.3 per
year). These data suggest that in patients with AERD and renal
failure requiring dialysis the potential for renal function recov-
ery and patient survival may not be influenced by dialysis
modality.
The findings of our study should be interpreted with caution.
First, the observational nature of the data does not allow any
firm conclusion on benefits and harms deriving from the choice
of peritoneal dialysis over hemodialysis. In fact, the results of
our study may not represent the true effects of the exposure but
may be confounded by indication. If patients with worse prog-
noses received a superior treatment, results would be leveled
off toward the null hypothesis. The opposite would have oc-
curred if an inferior dialysis method were assigned to those
with worse prognoses. Only randomized trials would provide
reliable information to guide clinical decision-making. How-
ever, given the relatively rare occurrence of the disorder, only
a very large, multicenter trial would be adequately powered to
answer the question. Second, the effect of dialysis modality
may be affected by local factors such as infrastructures, human
resources, preferences, and experience. For example, some de-
gree of variability in the anticoagulation schedule, dialysis du-
ration, and intensity may have, to some extent, affected the
outcome. It is possible that peritoneal and extracorporeal dial-
ysis modalities have similar performances when these local
factors are accounted for. To enhance external validity (gener-
alization) a multicenter clinical trial should account for these
clustering effects as we did in the analysis of the observational
data presented here using random effects modeling. Finally,
although our study is the largest longitudinal study reported so
far, it remains relatively small and unbalanced because most
patients received hemodialysis. This has implications on the
likelihood to detect an effect if this effect existed. In fact, a
sample of 110 individuals has a power of 80% to detect as
significant at the two-sided P level of 0.05, only large effects
(risk ratios 0.5 or 1.5) when baseline risks are high (0.5).
Unfortunately, the wide confidence intervals around the haz-
ard ratio for death in our study are consistent with this range of
possible effects of peritoneal versus hemodialysis. On the other
hand, the estimated effect most compatible with our study data
(“point estimate” or “best guess”) is close to the point of “zero
effect,” whereas more extreme values are progressively less
likely. To detect as significant such small and possibly clinically
irrelevant effects (e.g., a hazard ratio of 0.9), several thousand
patients would be necessary.
In conclusion, acute/subacute atheroembolism may require
dialysis treatment in 40% of the patients. These patients carry a
high risk of mortality. One quarter of them may recover suffi-
cient kidney function to stop dialysis. Data from the study
presented here, although observational in nature, do not sup-
port the notion that one dialysis modality is superior to the
other in such patients in terms of renal or patient outcomes.
Disclosures
None.
Figure 1. Kaplan–Meier survival curve of time to patient death
from dialysis initiation (Log-rank P  0.705). Effect estimation
with Cox’s regression: unadjusted hazard ratio 0.88, 95% con-
fidence interval 0.48 to 1.62.
Figure 2. Predicted patient survival probabilities by dialysis
type from frailty Cox’s regression (observations n  111, death
n  58). Model adjusted for age, gastrointestinal tract involve-
ment, center effect, and use of statins. Effect estimation: ad-
justed hazard ratio 0.90, 95% confidence interval 0.48 to 1.70
(Wald test P  0.756).
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